Every day, one story that matters, broken down into three numbered scenarios, each with its own probability. Never fixed — it shifts as the situation changes.
Scénario
Friday, science
Ozempic, Wegovy: Medical revolution or remedy for the wealthy?
Can new anti-obesity drugs (Ozempic, Wegovy, Mounjaro) stem the global epidemic, or will they remain reserved for the wealthy?
Publié le 25 septembre 2026
Share:
The facts
A profound medical shift is taking place in pharmacies worldwide with the mass arrival of GLP-1 agonists*, synthetic molecules that mimic a natural digestive hormone to regulate appetite and metabolism. Initially developed to treat type 2 diabetes, these weekly injections are seeing unprecedented success. Two pharmaceutical giants dominate this nascent market: Denmark’s Novo Nordisk, the historical manufacturer of semaglutide marketed as Ozempic and Wegovy, and US group Eli Lilly, creator of tirzepatide sold under the brand names Mounjaro and Zepbound. Faced with surging demand across every continent, both companies are investing billions of dollars to expand manufacturing capacity and keep pace with medical prescriptions.
The enthusiasm now extends far beyond cosmetic promises or glycemic control alone. On March 8, 2024, the FDA*, the US drug regulator, crossed a decisive milestone by approving Wegovy for cardiovascular risk reduction in overweight adults with established heart disease. This landmark regulatory decision draws directly on the findings of the landmark SELECT clinical trial, published in summer 2023 in the New England Journal of Medicine. Conducted on over seventeen thousand participants, the study showed that semaglutide delivered a 20% reduction in major adverse cardiovascular events, notably heart attacks and strokes, scientifically validating the life-saving potential of this drug class well beyond mere weight management.
Understanding it
A key to understanding the mechanism of action of GLP-1 agonists.
In the human body, the GLP-1 hormone naturally signals fullness to the brain as the stomach fills during a meal. Next-generation drugs like semaglutide mimic this biological molecule but resist digestive degradation much longer. They slow gastric emptying and send a continuous satiety signal, mechanically reducing daily caloric intake without requiring unbearable voluntary dietary restriction.
Yet the global public health emergency is immense and continues to grow rapidly. According to data published by the World Health Organization, obesity now affects 16% of adults worldwide, representing nearly one billion people exposed to debilitating chronic complications. In France, epidemiological findings are just as concerning, with the country counting 8 million obese individuals, or roughly 17% of its adult population. This complex chronic disease generates major human costs as well as considerable hospital expenditures for public finances, while conventional approaches relying solely on diet and physical activity often struggle to sustainably curb the most severe forms.
The financial barrier, however, represents the primary obstacle to the equitable rollout of these innovations. In the United States, Wegovy’s list price reaches roughly $1,000 per month without insurance, a prohibitive cost that effectively shuts out low-income households, who statistically face the highest rates of obesity. In France, the Haute Autorité de santé and the national health insurance system drastically restrict reimbursement, limiting it to a fraction of patients suffering from severe obesity with serious comorbidities. This high pricing underpins a dramatic market outlook: industry analysts project global demand for these cutting-edge therapies to exceed $150 billion by 2030, creating a colossal yet deeply unequal pharmaceutical windfall.
Understanding it
A key to understanding the economic equation behind treatment costs.
Pricing a chronic treatment at one thousand dollars a month creates an intractable budgetary dilemma for public health insurance systems. If a government were to reimburse its entire eligible population, total spending would quickly outstrip the annual operating budgets of multiple public hospitals. Public payers therefore choose to restrict access to life-threatening emergencies alone, leaving other patients to shoulder an impossible financial burden on their own.
Several major scientific and economic uncertainties nevertheless temper this initial optimism. First, the long-term side effects of continuous treatment over ten or twenty years remain only partially documented, particularly regarding gastrointestinal and pancreatic risks. Second, discontinuing injections frequently triggers rapid weight regain, turning these drugs into exceptionally costly lifelong prescriptions. Furthermore, pharmaceutical patents aggressively protect the original manufacturers, preventing the arrival of cheaper generics before roughly 2030 in major Western markets, which rules out any spontaneous drop in prices.
Three contrasting paths are therefore taking shape for the years ahead. A first outcome would see rapid democratization through public health agreements, turning these molecules into an accessible standard of care for the broad population. Conversely, persistent high prices could entrench a deep healthcare divide, restricting cardiovascular prevention to affluent classes in wealthy nations. Finally, the emergence of unexpected adverse effects or legal challenges could abruptly stall adoption, forcing health regulators to tighten prescription rules.
Global obesity prevalence (WHO)16% of adults in 2024, on a steadily rising trajectory
Estimated global GLP-1 demand in 2030$150B global projection, up from a few billion in 2020
Monthly Wegovy price in the US (without insurance)~$1,000 2024 list price, a major access barrier
New weight-loss treatments: global medical revolution or privilege reserved for the wealthy?
What we're assessing
FavorableUne généralisation des traitements fait reculer l'obésité et allège durablement le fardeau des maladies cardiovasculaires.
StableLes prix restent élevés et réservent les molécules aux pays riches et aux patients les plus fortunés.
DégradéDes effets indésirables graves et des coûts prohibitifs limitent drastiquement l'usage de ces nouvelles thérapies.
Favorable
25%
Unlikely
Democratization of treatments and sharp decline in chronic complications
Under this optimistic outlook, international health authorities treat obesity as a top preventive priority and negotiate sweeping price cuts with Novo Nordisk and Eli Lilly. Industrial manufacturing expands swiftly through new facilities and voluntary licensing agreements, ensuring broad pharmacy supply without shortages. Health insurance programs agree to cover prescriptions for millions of citizens, anticipating substantial downstream savings on dialysis, heart attacks, and complex bariatric surgeries.
This scenario departs sharply from the status quo by breaking the price barrier, turning what was once seen as a lifestyle drug into a true population-wide health lever. Unlike the adverse scenario where medical skepticism takes over, accumulating clinical data confirms reassuring long-term safety. Public healthcare systems would see cardiovascular hospitalizations drop markedly by the end of the decade, delivering substantial societal and financial benefits to solidarity-based public health models.
Indicators affected
Prévalence de l'obésité dans le monde (OMS)13 %↓16 %
Demande mondiale estimée de GLP-1 en 2030180 Md$↑150 Md$
Prix mensuel de Wegovy aux États-Unis250 $↓~1 000 $
The France angleSocial Security expands reimbursement, eventually lowering expenditures tied to chronic illnesses. ↑ Rather favorable for France.
Stable
50%
Likely
Persistent high prices and health divide between affluent and low-income patients
Pharmaceutical companies maintain tight pricing policies to maximize returns on their exclusive investments before patents expire around 2030. Treatments thus remain largely out of reach across developing nations and, in wealthy countries, stay restricted to the most affluent patients or individuals with advanced, severe cardiovascular comorbidities. Global obesity continues its steady rise driven by cheap, ultra-processed industrial food, while medical innovation benefits only a narrow, solvent slice of the population.
This baseline path extends current trends in Western markets, where access to care remains deeply unequal. Unlike the favorable scenario of widespread coverage, public budgets refuse to shoulder the staggering cost of universal injection reimbursements. Compared to the worst-case scenario, the drugs continue to prove remarkably effective metabolically without major toxicity issues, sustaining highly profitable yet concentrated demand while leaving the broader public health crisis among lower-income communities unaddressed.
Indicators affected
Prévalence de l'obésité dans le monde (OMS)18 %↑16 %
Demande mondiale estimée de GLP-1 en 2030150 Md$→150 Md$
Prix mensuel de Wegovy aux États-Unis950 $→~1 000 $
The France angleRestricted access limits costs for the national health insurance system but perpetuates sharp territorial and social inequalities. ↓ Rather unfavorable for France.
Degraded
25%
Unlikely
Emergence of late-onset side effects, disillusionment, and regulatory tightening
Large-scale, multi-year epidemiological monitoring reveals severe complications underestimated during early trials, such as recurring pancreatic issues, irreversible digestive disorders, or concerning neurobiological signals. Faced with these safety alerts and discontinuation rates exceeding 50% after one year of continuous use, regulatory agencies mandate strict black-box warnings. Multiple class-action lawsuits target manufacturers over inadequate warnings regarding rapid weight regain following forced treatment cessation.
This adverse scenario shatters hopes for a magic pharmaceutical bullet against the global public health crisis. Unlike the other two scenarios where clinical confidence remains intact, medical prescription becomes highly defensive and restricted strictly to last-resort cases. Market enthusiasm cools abruptly, prompting governments to redirect budgets toward traditional nutritional prevention and food industry taxes, while millions of affected individuals are left without a validated therapeutic alternative.
Indicators affected
Prévalence de l'obésité dans le monde (OMS)19 %↑16 %
Demande mondiale estimée de GLP-1 en 203060 Md$↓150 Md$
Prix mensuel de Wegovy aux États-Unis400 $↓~1 000 $
The France angleAdditional safety restrictions block access to treatments and shift the burden onto hospitals. ↓ Rather unfavorable for France.
Ordres de grandeur indicatifs pour les 3 scénarios ci-dessus, estimés avec l'information disponible à la publication et réévalués si la situation change — jamais des prévisions garanties. Learn more about our method →
Key takeaways
Can new GLP-1 agonist treatments (Ozempic, Wegovy, Mounjaro) stem the global obesity epidemic, or will they remain an inaccessible privilege?
Obesity affects 16% of adults worldwide and 8 million people in France (17% of adults). Despite semaglutide reducing major cardiovascular events by 20% in the SELECT trial, its monthly cost exceeds $1,000 in the United States.
No, they will not be enough on their own: with a 50% probability, these drugs will remain reserved for the wealthiest patients or the most critical cases due to prohibitive costs and strict reimbursement criteria, allowing obesity to continue rising elsewhere.
The key milestones to monitor are expanded reimbursement decisions by the French National Authority for Health (HAS) and the arrival of the first semaglutide generics expected around 2030.
Moderately negative
Our assessment of the impact for France: moderately negative.the likely persistence of high prices and strict reimbursement criteria (a combined 75% probability across stable and degraded scenarios) will deprive the majority of the eight million affected French citizens of equitable preventive access.
Si tu devais retenir 1 chose
Le semaglutide permet une réduction de 20 % des événements cardiovasculaires majeurs, mais son prix mensuel de 1 000 $ sans couverture freine son déploiement mondial.
A class of synthetic drugs that mimic the action of the natural GLP-1 hormone to stimulate insulin secretion, slow digestion, and signal fullness to the brain.
FDA (Food and Drug Administration)
US federal agency responsible for regulating, supervising, and approving food products and pharmaceuticals for the market.
